Gachon University Gil Medical Center
| Republic of Korea | Thailand | Turkey | |
| Stem Cell Therapy | from AUD $1,059 | from AUD $2,580 | from AUD $10,322 |
| Plasmapheresis | from AUD $6,021 | from AUD $3,154 | from AUD $1,720 |
| Stem cell therapy for ALS (amyotrophic lateral sclerosis) | - | from AUD $35,839 | from AUD $43,007 |
No hidden fees – just official clinic prices. Pay at the clinic for Amyotrophic lateral sclerosis treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Amyotrophic lateral sclerosis treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Amyotrophic lateral sclerosis treatment journey.
Dr. Byung-hee Lee is a neurosurgeon at RE:YOUTH Clinic in South Korea. He is a founding member of the Korean Society of Interventional Neurology. He also helped found the Korean Stroke Society. Dr. Lee treats complex conditions like Parkinson's, Alzheimer's, and cerebral aneurysms.
South Korea offers Neuronata-R. This autologous bone marrow-derived stem cell therapy has conditional approval for ALS. Specialists also perform arterial stem cell therapy and direct infusion. Major centres like Severance Hospital and RE:YOUTH facilitate these treatments. They use JCI-accredited or Newsweek-ranked facilities across Seoul and Incheon.
Bookimed Expert Insight: Neuronata-R is the standard approved therapy. RE:YOUTH clinic distinguishes itself by limiting intake to two patients daily. This high-focus model lets Dr Byung-hee Lee customise arterial infusion protocols. This approach is rare, even in a major hub like Seoul. It typically suits patients seeking intensive, individualised interventional care.
South Korea offers Neuronata-R, a stem cell therapy for amyotrophic lateral sclerosis not yet approved in Australia. This treatment uses autologous bone marrow-derived mesenchymal stem cells. The Ministry of Food and Drug Safety granted it conditional approval in 2013 to slow disease progression.
Bookimed Expert Insight: While most international centres use spinal injections, specific Korean clinics like RE:YOUTH specialise in arterial stem cell delivery. This method aims for more direct targeting of neurological tissue. Dr Byung-hee Lee at this clinic is a founding member of the Korean Society of Interventional Neurology. He brings rare vascular expertise to ALS care.
Patient Consensus: Patients note South Korea provides rapid access to clinical trial options and regenerative therapies. They recommend getting written English summaries of all procedures. These summaries help Australian neurologists manage follow-up care.
Major South Korean tertiary hospitals provide ALS care through integrated neurology and rehabilitation teams. Facilities like Severance Hospital and Hanyang University Hospital specialise in combined therapy models. These centres coordinate neurologists, pulmonologists, and physiotherapists to manage motor neuron symptoms. This approach aims to improve quality of life.
Bookimed Expert Insight: Large university hospitals like Severance manage massive patient volumes. In contrast, smaller specialised clinics such as RE:YOUTH restrict intake to 2 patients daily. This allowing patients to choose between high-capacity research environments and high-attention VIP settings.
Korean ALS centres prioritise long-term survival through invasive ventilation more frequently than Western clinics. While standards often focus on palliative care, specialists here frequently use tracheostomies. This approach extends life significantly for patients facing respiratory failure within JCI-accredited facilities like Severance Hospital.
Bookimed Expert Insight: South Korea leads in combining conventional neurology with regenerative techniques. Major centres like Severance Hospital hold JCI and KOIHA accreditations. Meanwhile, smaller specialised clinics like RE:YOUTH offer unique arterial stem cell infusions. This medical landscape allows patients to access both intensive respiratory support and experimental therapies. These options are often unavailable in other regions.
Patient Consensus: Patients note it is important to start non-invasive ventilation early for better quality of life. In Korea, families should clarify emergency contact pathways. They should also ask how doctors explain the transition to long-term ventilation.
International patients can access amyotrophic lateral sclerosis (ALS) research and specialised therapies in South Korea. Facilities like Severance Hospital and Gachon University Gil Medical Center participate in global studies. Research initiatives like the Pan-Asian Consortium for Treatment and Research in ALS (PACTALS) facilitate regional trial access.
Bookimed Expert Insight: South Korea is a top-tier destination for neurological care. It ranks 6th globally by patient requests. Large hospitals like Severance manage 4,000,000 patients annually. In contrast, smaller VIP clinics such as RE:YOUTH limit intake to two patients daily. This allow patients to choose between high-volume research centres or personalised regenerative therapy environments.
Patient Consensus: Patients note that private treatment is accessible. However, joining a trial requires careful planning for repeated international travel. Long-term trials often have strict residency-based eligibility rules. Logistics like visa requirements and mobility support must be confirmed with the investigator before travelling to South Korea.